Pfizer Aims To Revive Drug Candidates Through Gene Logic Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
Gene Logic will screen unapproved compounds for possible new indications with the goal of returning them to clinical development.
You may also be interested in...
Gene Logic Adds Lilly To Its Drug Rescue Roster
Company will reconsider drug candidates that were “discontinued or de-prioritized” for non-safety reasons and could even license them if Lilly opts out.
Gene Logic Adds Lilly To Its Drug Rescue Roster
Company will reconsider drug candidates that were “discontinued or de-prioritized” for non-safety reasons and could even license them if Lilly opts out.
Pfizer’s COX-2 Parecoxib Is “Not Approvable”
Company plans to meet with FDA regarding status of injectable COX-2 agent “as soon as possible.”